Kindstar Globalgene Technology, Inc.
KDGTF
Other OTC0.68
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
18.02
3Y
- -
64.11
5Y
- -
70.77
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Shiang Huang
- Full Time Employees
- 3,052
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- Biolake D2-1 Wuhan People's Republic of China
- IPO Date
- Dec 16, 2021
- Website
- kindstar.com.cn
- Similar Companies
- Business
- Kindstar Globalgene Technology, Inc. (KDGTF) operates as a leading provider of medical testing and diagnostic services in China, specializing in clinical testing solutions for diseases and health management. The company offers a comprehensive portfolio of laboratory testing services, including genetic testing, pathology diagnostics, microbiological testing, biochemical testing, and immune testing; it also provides specialized services such as newborn genetic screening, tumor gene detection, pharmacogenomics testing, and reproductive health management through its proprietary platforms and accredited labs. Kindstar serves hospitals, clinics, pharmaceutical companies, and individual consumers across China, with operations primarily concentrated in major cities like Beijing and Shanghai. Founded in 2003 and headquartered in Beijing, China, Kindstar Globalgene Technology, Inc. focuses on the precision medicine and clinical diagnostics industry, targeting the growing demand for advanced genetic and molecular testing in Asia. The company maintains a network of over 200 laboratories and service centers nationwide, supported by its CLIA-certified and CAP-accredited facilities for high-quality, standardized testing. It caters to key segments such as oncology, rare diseases, infectious diseases, and hereditary conditions, positioning itself as a pioneer in China's in vitro diagnostics market. In recent developments, Kindstar announced its rebranding and global expansion strategy in 2024, enhancing its international presence through strategic partnerships with overseas diagnostic firms. The company completed a significant funding round in early 2025, raising capital to accelerate new product launches in next-generation sequencing (NGS) panels for cancer diagnostics and AI-driven health analytics services. Additionally, Kindstar acquired a regional pathology network in southern China in late 2024, bolstering its service capabilities and market share in high-growth provinces.